Bridgewater Advisors Inc. Has $1.03 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Bridgewater Advisors Inc. increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,017 shares of the medical device company’s stock after purchasing an additional 433 shares during the quarter. Bridgewater Advisors Inc.’s holdings in DexCom were worth $1,031,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in shares of DexCom by 2.2% during the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares during the last quarter. Jennison Associates LLC grew its holdings in DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after acquiring an additional 6,544,102 shares during the last quarter. Legal & General Group Plc raised its stake in shares of DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after acquiring an additional 49,076 shares during the last quarter. Groupama Asset Managment lifted its holdings in shares of DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after purchasing an additional 31,358 shares during the period. Finally, Westfield Capital Management Co. LP raised its position in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $84.38 on Monday. The business’s fifty day simple moving average is $78.17 and its two-hundred day simple moving average is $77.75. The company has a market cap of $32.96 billion, a price-to-earnings ratio of 50.53, a P/E/G ratio of 2.00 and a beta of 1.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Analyst Ratings Changes

A number of equities analysts recently commented on DXCM shares. Citigroup lifted their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $86.00 to $104.00 in a report on Thursday. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Finally, Canaccord Genuity Group lifted their price target on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.30% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.